Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111692 · ClinicalTrials.gov registry record
A Prospective Observational Study of Foam Sclerotherapy .
A clinical trial of Autosomal Dominant Polycystic Kidney and Renal Cyst, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT04111692 is a study of Autosomal Dominant Polycystic Kidney and Renal Cyst that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 100 participants, above the 88-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04111692, a study of Autosomal Dominant Polycystic Kidney and Renal Cyst, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2027-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04111692
The ClinicalTrials.gov registry entry for NCT04111692 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (14% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Autosomal Dominant Polycystic Kidney appearing as the primary indexed condition, and to 0 interventions.
NCT04111692 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04111692 about?
NCT04111692 is a clinical study titled "A Prospective Observational Study of Foam Sclerotherapy .". An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominan...
What is the current status of trial NCT04111692?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2017-11-06. Estimated completion is 2027-11.
What conditions does trial NCT04111692 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney, Renal Cyst, Autosomal Dominant Polycystic Liver Disease, Hepatic Cyst.
Who is sponsoring clinical trial NCT04111692?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04111692 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
RECRUITING · Phase 2
-
Statin Therapy in Patients With Early Stage ADPKD
ACTIVE NOT RECRUITING · Phase 4
-
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
-
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.